Toxic Exposures Translational Research Award | HT942524TERPTRA

Frequently Asked Questions (FAQs)

What is the Toxic Exposures Translational Research Award (TERP TRA)?

The Toxic Exposures Translational Research Award (TERP TRA) is a discretionary federal grant program focused on translational research related to military-relevant toxic exposures. Its goal is to move strong scientific ideas closer to practical, real-world clinical use rather than supporting basic discovery alone.

What is the funding opportunity number for this grant?

The funding opportunity number (FON) is HT942524TERPTRA.

Which federal agency is offering this opportunity?

This opportunity is offered by the Department of the Army through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

What funding activity category does this opportunity fall under?

It falls under the Science and Technology and other Research and Development funding activity category.

What is the CFDA number associated with this program?

The opportunity is associated with CFDA 12.420.

When was the TERP TRA program created?

The program was created on June 26, 2024.

What is the original application closing date?

The original application closing date is November 7, 2024.

Who is eligible to apply?

Eligibility is listed as unrestricted. That means the opportunity is broadly open to applicants and is not limited to a narrow set of institution types based on the information provided.

What is the core purpose of the FY24 TERP TRA?

The core purpose is to fund translational research focused on military-related toxic exposures, with an emphasis on accelerating the movement of promising research findings toward practical outcomes that can be used in health care settings.

Is this program intended to fund basic research?

The emphasis is not on basic discovery for its own sake. Projects should be designed to accelerate translation to practical clinical outcomes, connecting scientific findings to credible and achievable clinical applications.

What kinds of end products are expected or encouraged?

The notice indicates that desired end products can include health care products (such as diagnostics or therapeutic approaches), interventions (such as prevention or treatment strategies), technologies (tools or platforms that enable better detection, monitoring, or care), and/or clinical practice guidelines (evidence-backed recommendations for clinicians).

What does "translational research" mean in this opportunity?

Translational research is described as an intentional integration of basic science and clinical observations. Projects should connect mechanistic or laboratory insights with patient-centered or clinically relevant data, and they should be designed so that eventual clinical application is credible and achievable.

What does the opportunity mean by "bidirectional" or "reciprocal" flow?

A key expectation is back-and-forth information flow between basic and clinical components. Clinical observations should help shape laboratory experiments and target selection, while laboratory findings should inform clinical hypotheses, biomarker development, patient stratification approaches, or the design of future clinical studies.

Can an application include both basic science and clinical elements?

Yes. In fact, the opportunity expects an integrated approach that ties mechanistic/basic insights to clinically relevant observations or data and shows how they inform each other as part of the research plan.

Can an application treat basic and clinical work as separate tracks?

The program expects the basic and clinical components to be connected through concrete, demonstrated back-and-forth interaction. The information provided indicates applicants should avoid presenting basic and clinical activities as loosely related or isolated components.

What topic area must the research address?

Projects must focus on military-related toxic exposures, with the translational intent of moving findings toward clinical use.

Are New Approach Methodologies (NAMs) allowed?

Yes. The announcement notes that New Approach Methodologies (NAMs) may be used.

Does the opportunity list specific NAM examples?

No specific examples are listed in the information provided. The general intent described is to support modern approaches that improve relevance, reduce uncertainty, or speed translation, such as advanced in vitro human-relevant systems, computational approaches, or modeling methods, when they strengthen the link between exposure science, biological effects, and clinical decision-making.

How many awards does the program expect to make?

The opportunity anticipates making approximately six awards.

Is the maximum award amount (ceiling) provided in the summary?

No. The public summary described here does not specify an award ceiling amount.

Where can applicants find information on budget constraints and allowable costs?

Based on the information provided, applicants would need to consult the full funding announcement or related guidance to identify budget constraints, allowable costs, and other requirements.

What is the overall positioning of the TERP TRA program?

It is positioned as a translational pipeline accelerator: it is intended to take promising military toxic exposure research and push it toward deliverables that can realistically influence clinical care, tools/technologies, interventions, and/or clinical practice guidelines.